Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses

Blood Cancer Journal

Volumn 6, Issue 5, 2016, Pages

  de Haart, S J ^a   Willems, S M ^a   Mutis, T ^b   Koudijs, M J ^a   van Blokland, M T ^a   Lokhorst, H M ^b   de Weger, R A ^a   Minnema, M C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; BIOPSY; BONE TUMOR; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; PLASMACYTOMA; PROCEDURES; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR;

ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY; BONE NEOPLASMS; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; TRANSCRIPTOME;

EID: 84983663787     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2016.35     Document Type: Letter

References (15)

1. Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma 2013; 54: 1135–1141.
2. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood 2014; 124: 3212–3221.
3. Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant 2008; 41: 779–784.
4. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol 2015; 20: 413–422.
5. Lohr J, Stojanov P, Carter S, Cruz-Gordillo P, Lawrence M, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91–101.
6. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013; 3: 862–869.
7. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IMS. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317–323.
8. Hoogstraat M, Hinrichs JWJ, Besselink NJM, Radersma-van Loon JH, de Voijs CMA, Peeters T et al. Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology. J Mol Diagn 2015; 17: 10–18.
9. Ercan C, van Diest PJ, van der Ende B, Hinrichs J, Bult P, Buerger H et al. p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast. Cell Oncol (Dordr) 2012; 35: 111–118.
10. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582–584.
11. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014; 123: 632–639.
12. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001; 18: 212–224.
13. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128–135.
14. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18: 290–300.
15. Bladé J, Fernández De Larrea C, Rosiñol L, Cibeira MT, Jimènez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extra-medullary spread, and treatment approach. J Clin Oncol 2011; 29: 3805–3812.